Company / R&D per Share
ALNYLAM PHARMACEUTICALS, INC. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$10.21
FY2025
5-year range
$5.45 / $10.21
FY2021-FY2025
Trend
+14.0%
vs FY2024
Sector context
#17 of 208
Health Care
What the data says
Among 208 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the top 8% for r&d per share. R&D per Share has increased for 3 consecutive years, from $5.45 in FY2022 to $10.21 in FY2025.
Based on SEC 10-K filings.
10.21 in FY2025 with a 5-year CAGR of +17.8%. Top quartile in the Health Care sector.
Improved from $8.11 to $10.21 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +23.3%
- 5-Year CAGR
- +17.8%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 208This company $10.21 Sector average $12.19
▼
-16.3% below sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 14.0% year-over-year.
- Ranks #17 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.21 | +14.0% |
| FY2024 | $8.95 | +10.5% |
| FY2023 | $8.11 | +48.8% |
| FY2022 | $5.45 | -3.2% |
| FY2021 | $5.63 | +24.9% |
| FY2020 | $4.51 | +16.7% |
| FY2019 | $3.86 | +0.6% |
| FY2018 | $3.84 | -11.1% |
| FY2017 | $4.31 | -3.4% |
| FY2016 | $4.47 | +35.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026